What were Windlas Biotech Ltd's latest quarterly results?
Windlas Biotech Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: 0.0%
- Revenue Growth YoY: +17.2%
- Operating Margin: 11.0%
Windlas Biotech Ltd: Stock Analysis & Fundamentals
Updated this weekWindlas Biotech Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 26.8. ROE: 12.2%. This stock is not currently in the Nifty 500 momentum outperformers list.
Windlas Biotech Ltd Key Facts
What's Happening
💪Debt reduced 11% YoY — balance sheet strengthening
👔Promoter stake down 0.5% this quarter
🌐FII stake decreased 0.9% this quarter
🏛️DII accumulation — stake up 1.9%
Key Numbers
Current Price
₹864
Dividend Yield
0.67%
Market Cap
1.8K Cr
Valuation
N/AOther Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Windlas Biotech Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Windlas Biotech Ltd's current PE ratio?
Windlas Biotech Ltd's current PE ratio is 26.8x.
- Current PE: 26.8x
- Market Cap: 1.8K Cr
- Dividend Yield: 0.67%
What is Windlas Biotech Ltd's price-to-book ratio?
Windlas Biotech Ltd's price-to-book ratio is 3.1x.
- Price-to-Book (P/B): 3.1x
- Book Value per Share: ₹275
- Current Price: ₹864
Is Windlas Biotech Ltd a fundamentally strong company?
Windlas Biotech Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 16.0%
Is Windlas Biotech Ltd debt free?
Windlas Biotech Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹35 Cr
What is Windlas Biotech Ltd's return on equity (ROE) and ROCE?
Windlas Biotech Ltd's return ratios over recent years
- FY2024: ROCE 18.0%
- FY2025: ROCE 17.0%
- FY2026: ROCE 16.0%
Is Windlas Biotech Ltd's cash flow positive?
Windlas Biotech Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹105 Cr
- Free Cash Flow (FCF): ₹13 Cr
- CFO/PAT Ratio: 159% (strong cash conversion)
What is Windlas Biotech Ltd's dividend yield?
Windlas Biotech Ltd's current dividend yield is 0.67%.
- Dividend Yield: 0.67%
- Current Price: ₹864
Who holds Windlas Biotech Ltd shares — promoters, FII, DII?
Windlas Biotech Ltd's shareholding pattern (May 2026)
- Promoters: 63.3%
- FII (Foreign): 1.0%
- DII (Domestic): 10.2%
- Public: 25.5%
Is promoter holding increasing or decreasing in Windlas Biotech Ltd?
Windlas Biotech Ltd's promoter holding has increased recently.
- Current Promoter Holding: 63.3% (May 2026)
- Previous Quarter: 61.9% (Mar 2026)
- Change: +1.41% (increasing — positive signal)
Is Windlas Biotech Ltd a new momentum entry or an established outperformer?
Windlas Biotech Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Windlas Biotech Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Windlas Biotech Ltd may be worth studying
- Cash flow is positive — CFO ₹105 Cr
What is the investment thesis for Windlas Biotech Ltd?
Windlas Biotech Ltd investment thesis summary:
What is the future outlook for Windlas Biotech Ltd?
Windlas Biotech Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.